NanoViricides, EBIT per Share
The EBIT per Share of NanoViricides, (NNVC) as of Aug 12, 2026 is -0.48 USD. In the previous year, EBIT per Share was -0.58 USD — a change of -17.32% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.48USD
YoY
-17.32%
Last updated:
EBIT per Share of NanoViricides, is 2026 -0.48 USD. EBIT per Share of NanoViricides, was 2025 -0.58 USD. It decreases by -17.32% higher compared to the previous year.
Access this data via the Eulerpool API
NanoViricides, Stock analysis
What does NanoViricides, do? NanoViricides Inc. is a biopharmaceutical company specializing in the development of therapeutics for the treatment of virus infections. The company's unique technology is based on nanoparticles that specifically target and destroy virus cells.
The company was founded in 2005 by Farooq Ansari, a former top manager at Pfizer. Together with his team, he quickly recognized the potential of nanotechnology in combating diseases and began developing various products based on this technology.
NanoViricides Inc.'s business model is based on the development and commercialization of nanoparticle-based therapeutics in the global health market. The company works closely with leading research and development institutions to expand knowledge and technology in this field.
NanoViricides Inc. has several product divisions specializing in combating different virus infections. The main divisions are:
- FluCide: Focuses on the development of therapeutics for the treatment of influenza infections. Flu is one of the most widespread virus infections worldwide and can lead to serious complications such as pneumonia.
- HerpeCide: Focuses on the development of therapeutics for the treatment of herpesvirus infections, including genital herpes, shingles, and chickenpox.
- HIVCide: Focuses on the development of therapeutics for the treatment of HIV infections, aiming to develop a safer and more effective cure for HIV.
- RabiCide: Focuses on the development of therapeutics for the treatment of rabies infections.
- CoronaCide: Focuses on the development of therapeutics for the treatment of coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.
NanoViricides Inc. has a range of products in various stages of development and research, with some already in clinical studies. The company continuously strives to improve its products and expand its research and development efforts.
In summary, NanoViricides Inc. is a biopharmaceutical company specializing in the development of therapeutics for the treatment of virus infections. It utilizes a unique technology based on nanoparticles to directly combat viruses at the cellular level. With multiple product divisions and a strong team of researchers and developers, NanoViricides Inc. is continuously working to improve the health of patients worldwide.
The answer is: NanoViricides Inc. is a biopharmaceutical company specializing in the development of therapeutics for virus infections using nanoparticle-based technology. NanoViricides, is one of the most popular companies on Eulerpool.
Frequently Asked Questions about NanoViricides, stock
EBIT per Share of NanoViricides, is -0.48 USD in 2026.
EBIT per Share of NanoViricides, changed from -0.58 USD to -0.48 USD, representing a -17.32% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share NanoViricides, since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — NanoViricides,
All Key Metrics — NanoViricides,
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth